Thomas Wolfram Paul Friedl

14PUBLICATIONS
67CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples midwifery and paediatricsAboriginal and Torres Strait Islander theory of change models for health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 06, 2026
Targeting common denominators of DNA damage tolerance mechanisms as therapeutic strategy to cope with dynamic phenotypic changes in triple-negative breast cancer cells.

|Sep 04, 2026
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.

|Nov 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy.

Kerstin Pfister, Thomas W P Friedl, Andreas Hartkopf

|Sep 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer.

Kerstin Pfister, Sophia Huesmann, Angelina Fink

|Sep 09, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors.

Tatjana Braun, Sophia Huesmann, Kerstin Pfister

|May 14, 2025
Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer.

Stefan Lukac, Visnja Fink, Davut Dayan

Pageof 3

Frequent Collaborators

4 joint publications

Wolfgang Janni

3 joint publications

Kerstin Pfister

3 joint publications

Lisa Wiesmüller

3 joint publications

Stefan Lukac